Altamira Therapeutics, a preclinical-stage biopharmaceutical company, has reported significant developments in its RNA delivery technology and product candidates. The company's OligoPhore™ and SemaPhore™ platforms are designed for efficient RNA delivery to extrahepatic tissues, with two flagship siRNA programs, AM-401 for KRAS driven cancer and AM411 for rheumatoid arthritis, showing progress beyond in vivo proof of concept. Altamira has also spun off a 51% stake in Altamira Medica AG, retaining a 49% interest in the Bentrio® business. The company has published research demonstrating the effectiveness of its technology in reducing tumor growth and treating abdominal aortic aneurysm in animal models. Additionally, Altamira has filed provisional patent applications related to its delivery platforms and has entered into a collaboration agreement with Univercells Group...Show More

Altamira Therapeutics, a preclinical-stage biopharmaceutical company, has reported significant developments in its RNA delivery technology and product candidates. The company's OligoPhore™ and SemaPhore™ platforms are designed for efficient RNA delivery to extrahepatic tissues, with two flagship siRNA programs, AM-401 for KRAS driven cancer and AM411 for rheumatoid arthritis, showing progress beyond in vivo proof of concept. Altamira has also spun off a 51% stake in Altamira Medica AG, retaining a 49% interest in the Bentrio® business. The company has published research demonstrating the effectiveness of its technology in reducing tumor growth and treating abdominal aortic aneurysm in animal models. Additionally, Altamira has filed provisional patent applications related to its delivery platforms and has entered into a collaboration agreement with Univercells Group to evaluate mRNA vaccine delivery. Financially, Altamira announced a public offering of common shares and warrants, which closed with gross proceeds of $4.0 million. The company also has an 'at-the-market' program with H.C. Wainwright & Co., LLC, which has generated $1.66 million in gross proceeds from the sale of shares. Altamira's financial statements reflect a net loss from continuing operations of $4.339 million for the six months ended June 30, 2024, a decrease from the previous year's loss of $4.524 million. The company's cash position as of June 30, 2024, was $65 thousand, with additional funding expected from the recent public offering, warrant exercises, and potential divestiture or partnering of the AM-125 program. Altamira anticipates its cash and funding sources will support operations through August 2025.